These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37053354)

  • 1. [External quality control of immunohistochemical studies in pathomorphology: tasks, problems, solutions, development prospects].
    Zavalishina LÉ; Vasilyeva AI; Kuznetsova OA; Skrypnikova KA; Frank GA
    Arkh Patol; 2023; 85(2):48-52. PubMed ID: 37053354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the work of the Immunohistochemical Quality Control Center of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia in 2023].
    Zavalishina LE; Artemyeva AS; Vtorushin SV; Kuznetsova OA; Leenman EE; Petrov SV; Savelov NA; Vasilyeva AI; Skrypnikova KA; Frank GA
    Arkh Patol; 2024; 86(3):38-45. PubMed ID: 38881004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of the work of the Russian Medical Academy of Continuous Professional Education Center for quality control of immunohistochemical studies for 2019-2021].
    Zavalishina LÉ; Vasilyeva AI; Kuznetsova OA; Skrypnikova KA; Frank GA
    Arkh Patol; 2022; 84(2):72-76. PubMed ID: 35417952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 testing in the UK: further update to recommendations.
    Walker RA; Bartlett JM; Dowsett M; Ellis IO; Hanby AM; Jasani B; Miller K; Pinder SE
    J Clin Pathol; 2008 Jul; 61(7):818-24. PubMed ID: 18381380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of tumor biological parameters in breast cancer: round robin testing for quality assurance].
    Liessem S; Winkens W; Jonigk D; Wasielewski RV; Fisseler-Eckhoff A; Rüschoff J; Kreipe HH
    Pathologe; 2014 Feb; 35(1):61-71. PubMed ID: 24496992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
    Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
    J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of intralaboratory and external quality control of immunohistochemical studies to improve the detection of estrogen and progesterone receptors].
    Kushnarev VA; Kudaibergenova AG; Zavalishina LE
    Arkh Patol; 2021; 83(3):5-9. PubMed ID: 33822548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Dual In Situ Hybridization: Correlations and Cautions.
    Troxell M; Sibley RK; West RB; Bean GR; Allison KH
    Arch Pathol Lab Med; 2020 Dec; 144(12):1525-1534. PubMed ID: 32101450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The first experience of external quality control of immunohistochemical studies in the diagnosis of lymphoproliferative diseases].
    Krivolapov IuA; Peshkov MV; Leenman EE; Matsionis AE; Kovrigina AM
    Arkh Patol; 2011; 73(2):25-32. PubMed ID: 21695985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.
    Bianchi S; Caini S; Paglierani M; Saieva C; Vezzosi V; Baroni G; Simoni A; Palli D;
    Pathol Oncol Res; 2015 Apr; 21(2):477-85. PubMed ID: 25367072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.
    Cheung CC; Garratt J; Won J; Cutz JC; Gilks BC; Tsao M; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2015; 23(10):677-81. PubMed ID: 26551338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ hybridization analysis of invasive breast carcinomas with immunohistochemically negative Her-2 status (a national multicenter study).
    Tuzlali S; Yavuz E; Canda T; Güray M; Geçer MO; Süllü Y; Sezer C; Süren D; Sak SD; Calay Z; Ilvan S; Zorludemır S; Ergın M; Karavelı FS; Peşterelı E; Ozdener F; Ustündağ K
    Turk Patoloji Derg; 2014; 30(2):87-93. PubMed ID: 24782296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].
    MacGrogan G; Mathieu MC; Poulet B; Penault-Llorca F; Vincent-Salomon A; Roger P; Treilleux I; Valent A; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
    Ann Pathol; 2014 Oct; 34(5):366-72. PubMed ID: 25439989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].
    Ngo C; Laé M; Ratour J; Hamel F; Taris C; Caly M; Le Cunff A; Reyal F; Kirova Y; Pierga JY; Vincent-Salomon A
    Bull Cancer; 2017; 104(7-8):608-617. PubMed ID: 28595742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
    Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: a United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers pilot experience.
    Paradiso A; Miller K; Marubini E; Pizzamiglio S; Verderio P
    J Clin Oncol; 2007 Aug; 25(22):e27-8. PubMed ID: 17664462
    [No Abstract]   [Full Text] [Related]  

  • 18. Testing for HER2 in breast cancer.
    Lewis F; Jackson P; Lane S; Coast G; Hanby AM
    Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ErbB2 diagnostics in breast cancer--an update].
    Rüschoff J; Nagelmeier I; Hofmann M; Henkel T; Stoss O
    Pathologe; 2009 Mar; 30(2):147-55. PubMed ID: 19214513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
    Rhodes A; Jasani B; Balaton AJ; Miller KD
    J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.